Study 3—PrEP in school children. More than 700 school
children, 4 to 8 y of age, were vaccinated with a two- or threedose
ID regimen (on days 0 and 28 or 0, 7 and 28) and examined
immunogenicity and safety after the primary vaccination series
(in a subset of about 100 subjects), as well as after two (simulated)
PEP booster doses on days 0 and 3 (as if an exposure had
occurred), one, three or five years after the primary vaccination
series (in all subjects).26,27 After the primary vaccination, all subjects
(30/30 = 100%) who received 3 doses of PCECV and 98%
(42/43) of those who had received 2 doses had VNA concentrations
≥ 0.5 IU/mL on day 49, indicative of an adequate immune
response.26 Over the year(s), VNA concentrations dropped as
expected, and 1, 3 or 5 y later only 35–46% (3 dose groups) and
7–12% (2 dose groups) had maintained adequate VNA concentrations.
27 However, when two booster doses were administered
three days apart, all children had an anamnestic response, reaching
VNA concentrations ≥ 0.5 IU/mL within one or two weeks,
regardless of the time interval between primary vaccination and
administration of booster doses. In this study for safety evaluation
only unsolicited serious adverse events were recorded. No
serious adverse event (AE) attributed to vaccine administration
occurred during the study.
Study 3—PrEP in school children. More than 700 school
children, 4 to 8 y of age, were vaccinated with a two- or threedose
ID regimen (on days 0 and 28 or 0, 7 and 28) and examined
immunogenicity and safety after the primary vaccination series
(in a subset of about 100 subjects), as well as after two (simulated)
PEP booster doses on days 0 and 3 (as if an exposure had
occurred), one, three or five years after the primary vaccination
series (in all subjects).26,27 After the primary vaccination, all subjects
(30/30 = 100%) who received 3 doses of PCECV and 98%
(42/43) of those who had received 2 doses had VNA concentrations
≥ 0.5 IU/mL on day 49, indicative of an adequate immune
response.26 Over the year(s), VNA concentrations dropped as
expected, and 1, 3 or 5 y later only 35–46% (3 dose groups) and
7–12% (2 dose groups) had maintained adequate VNA concentrations.
27 However, when two booster doses were administered
three days apart, all children had an anamnestic response, reaching
VNA concentrations ≥ 0.5 IU/mL within one or two weeks,
regardless of the time interval between primary vaccination and
administration of booster doses. In this study for safety evaluation
only unsolicited serious adverse events were recorded. No
serious adverse event (AE) attributed to vaccine administration
occurred during the study.
การแปล กรุณารอสักครู่..